 | |  | |  | |  | |  | |  | |  | |  |
| IJCEP Copyright © 2007-All rights reserved. |
| International Journal of Clinical and Experimental Pathology |
Int J Clin Exp Pathol 1(6):502-509;2008
Original Article
Loss of DNA Mismatch Repair Protein hMSH6 in Ovarian Cancer is Histotype-Specific
Qihui “Jim” Zhai, Daniel Gustavo Rosen, Karen Lu and Jinsong Liu
Department of Pathology, Methodist Hospital, Houston Texas; and the Departments of Pathology and 3Gynecology Oncology, The
University of Texas M. D. Anderson Cancer Center, Houston, Texas
Received 27 Dec 2007; accepted with revision 14 Jan 2008; available online 31 Jan 2008
grade, disease stage, familial history of cancer and patient survival. We stained an ovarian carcinoma tissue microarray consisting of
semiquantitatively as negative or positive. Twelve cases were excluded owing to loss of cores during staining. Absence of hMSH6 protein
formalin-fixed, paraffin-embedded tissue samples from 322 patients with an anti-hMSH6 antibody and scored the results was noted in 20
semiquantitatively as negative or positive. Twelve cases were excluded owing to loss of cores during staining. Absence of hMSH6 protein
in 1 of 14 malignant mixed Müllerian tumors, 2 of 6 mucinous carcinomas, 0 of 2 transitional cell carcinomas and in 0 of 8 undifferentiated
was noted in 20 of 230 serous carcinomas (8.7%), in 7 of 16 clear cell carcinomas (43.7%), in 4 of 34 endometrioid carcinomas (11.7%),
carcinomas. Loss of hMSH6 protein was not associated with survival, patient age, tumor grade, or disease stage but was associated with
in 1 of 14 malignant mixed Müllerian tumors, 2 of 6 mucinous carcinomas, 0 of 2 transitional cell carcinomas and in 0 of 8 undifferentiated
carcinomas. Loss of hMSH6 protein was not associated with survival, patient age, tumor grade, or disease stage but was associated with
clear cell, mucinous and endometrioid carcinoma histology (P<0.007). These findings indicate that loss of hMSH6 expression in ovarian
carcinoma is more common in certain histologic subtypes, particularly in clear cell, endometrioid, and mucinous carcinoma, suggesting
survival and was not associated with disease stage, tumor grade, patient age or family history of cancer. (IJCEP712005).
that loss of hMSH6 function may participate in the pathogenesis of these subtypes of cancer. Loss of hMSH6 expression did not predict
survival and was not associated with disease stage, tumor grade, patient age or family history of cancer. (IJCEP712005).
Original Article
Loss of DNA Mismatch Repair Protein hMSH6 in Ovarian Cancer is Histotype-Specific
Qihui “Jim” Zhai, Daniel Gustavo Rosen, Karen Lu and Jinsong Liu
Department of Pathology, Methodist Hospital, Houston Texas; and the Departments of Pathology and 3Gynecology Oncology, The
University of Texas M. D. Anderson Cancer Center, Houston, Texas
Received 27 Dec 2007; accepted with revision 14 Jan 2008; available online 31 Jan 2008
grade, disease stage, familial history of cancer and patient survival. We stained an ovarian carcinoma tissue microarray consisting of
semiquantitatively as negative or positive. Twelve cases were excluded owing to loss of cores during staining. Absence of hMSH6 protein
formalin-fixed, paraffin-embedded tissue samples from 322 patients with an anti-hMSH6 antibody and scored the results was noted in 20
semiquantitatively as negative or positive. Twelve cases were excluded owing to loss of cores during staining. Absence of hMSH6 protein
in 1 of 14 malignant mixed Müllerian tumors, 2 of 6 mucinous carcinomas, 0 of 2 transitional cell carcinomas and in 0 of 8 undifferentiated
was noted in 20 of 230 serous carcinomas (8.7%), in 7 of 16 clear cell carcinomas (43.7%), in 4 of 34 endometrioid carcinomas (11.7%),
carcinomas. Loss of hMSH6 protein was not associated with survival, patient age, tumor grade, or disease stage but was associated with
in 1 of 14 malignant mixed Müllerian tumors, 2 of 6 mucinous carcinomas, 0 of 2 transitional cell carcinomas and in 0 of 8 undifferentiated
carcinomas. Loss of hMSH6 protein was not associated with survival, patient age, tumor grade, or disease stage but was associated with
clear cell, mucinous and endometrioid carcinoma histology (P<0.007). These findings indicate that loss of hMSH6 expression in ovarian
carcinoma is more common in certain histologic subtypes, particularly in clear cell, endometrioid, and mucinous carcinoma, suggesting
survival and was not associated with disease stage, tumor grade, patient age or family history of cancer. (IJCEP712005).
that loss of hMSH6 function may participate in the pathogenesis of these subtypes of cancer. Loss of hMSH6 expression did not predict
survival and was not associated with disease stage, tumor grade, patient age or family history of cancer. (IJCEP712005).